BIOGEN IDEC (IDP HM) stock market data APIs
€128.4067
-0.15(-0.1%)
as of October 24, 2025
Try our APIs with
free plan!
BIOGEN IDEC Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for IDP.HM.
Prev. Close
128.4067
Open
128.2522
High
128.4067
Low
128.2522
52 wk Range
99.02-171.95
Market Cap
30 257 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get BIOGEN IDEC data using free add-ons & libraries
Get BIOGEN IDEC Fundamental Data
BIOGEN IDEC Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BIOGEN IDEC News
New
Can Biogen’s (BIIB) Immunology Pipeline Moves Reshape Its Competitive Edge in Autoimmune Disease?
Biogen and partner UCB recently announced upcoming presentations at the American College of Rheumatology 2025 conference highlighting positive Phase 3 data for dapirolizumab pegol in treating systemic...
Will Biogen Beat on Q3 Earnings? Leqembi, Skyclarys Could Hold the Key
We expect Biogen BIIB to beat expectations when it reports third-quarter 2025 results on Oct. 30, before market open. In the last reported quarter, the company's earnings beat expectations by 39.2%. ...
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
Biogen Inc. The oral C5aR1 antagonist is designed to modulate neutrophil-driven inflammation, a central mechanism underlying many inflammatory diseases CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (G...
3 Profitable Stocks We Steer Clear Of
While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is ...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
